login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

OSPREY trial completes US patient enrolment


Thursday, 12 Jul 2012 16:12
Misago
Misago

On 11 July, Terumo Interventional Systems announced the completion of US patient enrolment in the OSPREY (Occlusive/stenotic peripheral artery revascularization study) designed to evaluate the safety and effectiveness of the Misago Self-expanding Stent System. 


OSPREY is a single-arm, multicentre, non-randomised, prospective clinical trial for the treatment of atherosclerotic stenoses and occlusions of the superficial femoral artery that included 200 patients in 31 centres in the USA and 100 patients in seven centres in Japan.

A unique feature of this study is that it simultaneously enrolled patients in the USA and Japan as part of the larger Harmonization by Doing (HBD) pilot programme, a cooperative effort led by the FDA, the MHLW/PMDA (Japan’s regulatory body), Terumo Corporation, based in Tokyo, Japan, and Terumo Medical Corporation, based in Somerset, New Jersey, USA. The HBD initiative is intended to shorten the gap between product approvals in these two countries.


“Peripheral vascular disease is a leading cause of disability in the USA, affecting between 8 and 12 million Americans. It is critical that physicians, and their patients, have faster access to the latest technologies in order to maximise treatment options,” said J Fritz Angle, professor of Radiology, University of Virginia, and US principal investigator in the OSPREY trial. “I look forward to analysing and discussing the OSPREY data with all of the trial investigators. The international experience and testing efficiencies obtained from our collective participation in this HBD initiative could have a dramatic effect on the way important medical devices reach the market in the future.”


The MISAGO Self-expanding Stent consists of a nitinol stent pre-mounted on the distal portion of a rapid-exchange delivery catheter system. The stent has three radiopaque markers located on each end of the stent to help ensure accurate placement in the lesion. The stent is currently available for sale in Europe.

The first US patient implant in the OSPREY trial occurred in September 2010. The primary endpoints of the US arm of the OSPREY study are:

  • Primary stent patency rate at one year as confirmed by duplex ultrasound or angiography.
  • Freedom from major adverse events within 30 days of the procedure, which would result in target lesion revascularisation, amputation of the treated limb or death.

“OSPREY is Terumo Medical Corporation’s first US clinical trial for a premarket approval device and we are exceptionally pleased with its progress. Terumo is greatly appreciative of the tremendous support given by our US clinical investigators, which helped us meet the critical enrolment goal in this landmark HBD initiative,” said James Rushworth, president, Terumo Interventional Systems and Onset Medical Corporation. “The OSPREY trial and the MISAGO Stent truly speak to our three strategic pillars of introducing innovative technologies that create clinical, economic, and quality of life benefits.”




Add New Comment

Most popular


First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA

Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years
Wednesday, 19 Nov 2014
Three-year follow-up results of patients treated with the Supera stent show that nominal deployment or slight compression of the device delivers the best outcomes in terms of durability, and that ... Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years

Bioresorbable scaffolds can produce comparable acute results to metal stents
Tuesday, 04 Nov 2014
Speaking at the Asian Society for Vascular Surgery meeting (5–7 September, Hong Kong, China), Andrew Holden commented that studies indicate that bioresorbable scaffolds can produce comparable acute ... Bioresorbable scaffolds can produce comparable acute results to metal stents

Features


A new classification system for acute type B aortic dissection predicting reverse aortic remodelling
Wednesday, 19 Nov 2014
In recent years, primary stent grafting for complicated type B aortic dissection has been applied with favourable results. Thoracic aortic endovascular repair can be offered with a relatively low ... A new classification system for acute type B aortic dissection predicting reverse aortic remodelling

Resolving differences between carotid stenosis management guidelines
Wednesday, 19 Nov 2014
Anne Abbott, Melbroune, Australia, writes that while some variability in guideline recommendations is due to different publication dates, much is due to bias in what evidence is considered and how it ... Resolving differences between carotid stenosis management guidelines

Profiles


Martin Björck
Wednesday, 01 Oct 2014
Martin Björck, Uppsala University Hospital, Sweden, holds the only professor-chair of vascular ... Martin Björck

Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions